Author:
Wagner Bradley G.,Garcia-Lerma J. Gerardo,Blower Sally
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Heneine, W. When do minority drug-resistant HIV-1 variants have a major clinical impact? J Infect Dis 201, 647–649 (2010).
2. Paredes, R. et al. Pre-existing Minority drug-resistant HIV-1 variants, adherence and risk of antiretrovrial treatment failure. J Infect Dis 201, 662–671 (2010).
3. Li, J. Z. et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305, 1327–1335 (2011).
4. Cong, M. E., Heneine, W. & Garcia-Lerma, J. G. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol. 81, 3037–3041 (2007).
5. Cong, M. E. et al. Generation and mucosal transmissibility of emtricitabine and tenofovir-resistant SHIV162P3 mutants in macaques. Virology 412, 435–440 (2011).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献